Cartesian Therapeutics (RNAC) announced that Carsten Brunn, Ph.D., was named as Chairman of the Board of Directors, effective October 29, 2025. Dr. Brunn, who currently serves as the Company’s President and Chief Executive Officer and as a member of the Board, will succeed Carrie Cox, who is stepping down to focus on other responsibilities, including her recent appointment as Executive Chair of another publicly-traded company. In connection with Dr. Brunn’s assumption of the role of Chairman of the Board, Patrick Zenner, M.B.A., was named as Lead Independent Director of the Board.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics’ Descartes-08: A Promising Phase 3 Trial for Myasthenia Gravis
- Cartesian Therapeutics Advances Autoimmune Disorder Treatment with Descartes-08 Study
- Cartesian Therapeutics Advances SLE Treatment with Descartes-08 Study
- Cartesian Therapeutics Eliminates Chief Scientific Officer Role
- Cartesian Therapeutics Appoints New Chief Accounting Officer